SG Americas Securities LLC Invests $1.67 Million in Royalty Pharma PLC (NASDAQ:RPRX)

SG Americas Securities LLC bought a new position in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 53,487 shares of the biopharmaceutical company's stock, valued at approximately $1,665,000.

Several other institutional investors also recently bought and sold shares of the business. Adage Capital Partners GP L.L.C. boosted its holdings in shares of Royalty Pharma by 42.6% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 16,968,321 shares of the biopharmaceutical company's stock worth $432,862,000 after purchasing an additional 5,069,127 shares during the last quarter. Norges Bank purchased a new position in Royalty Pharma during the fourth quarter worth about $124,498,000. BNP Paribas Financial Markets acquired a new stake in Royalty Pharma in the 4th quarter worth about $41,959,000. AQR Capital Management LLC grew its holdings in Royalty Pharma by 187.0% in the 4th quarter. AQR Capital Management LLC now owns 1,903,676 shares of the biopharmaceutical company's stock valued at $48,563,000 after buying an additional 1,240,384 shares during the period. Finally, Wedge Capital Management L L P NC purchased a new stake in Royalty Pharma in the 1st quarter valued at about $31,591,000. 54.35% of the stock is currently owned by institutional investors and hedge funds.

Royalty Pharma Trading Up 1.0%

NASDAQ:RPRX traded up $0.35 on Thursday, hitting $34.91. 3,957,630 shares of the stock were exchanged, compared to its average volume of 3,631,742. The stock has a market cap of $19.63 billion, a PE ratio of 18.87, a PEG ratio of 1.77 and a beta of 0.48. The company has a current ratio of 1.56, a quick ratio of 1.56 and a debt-to-equity ratio of 0.68. The stock has a fifty day moving average of $33.00 and a 200-day moving average of $31.09. Royalty Pharma PLC has a fifty-two week low of $24.05 and a fifty-two week high of $35.38.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.99 by $0.07. Royalty Pharma had a net margin of 48.23% and a return on equity of 24.71%. The firm had revenue of $839.00 million during the quarter, compared to the consensus estimate of $724.69 million. As a group, equities analysts expect that Royalty Pharma PLC will post 4.49 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Stockholders of record on Friday, May 16th were given a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 2.52%. The ex-dividend date of this dividend was Friday, May 16th. Royalty Pharma's payout ratio is currently 47.57%.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on RPRX shares. Morgan Stanley started coverage on shares of Royalty Pharma in a report on Friday, May 16th. They set an "overweight" rating and a $51.00 price objective on the stock. Wall Street Zen lowered shares of Royalty Pharma from a "buy" rating to a "hold" rating in a research report on Tuesday, May 20th. Finally, Citigroup reiterated a "buy" rating on shares of Royalty Pharma in a report on Friday, March 28th. One equities research analyst has rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company's stock. According to data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $47.33.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.